MedTrace Logo

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

NCT03593993 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2023-10-06

No results posted yet for this study

Summary

This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.

Conditions

Interventions

PROCEDURE

Surgical Cohort

Blood, cerebrospinal fluid, and surgical tissue collected during procedure

Sponsors & Collaborators

  • Musella Foundation

    collaborator UNKNOWN

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Stuart Grossman, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • Karisa Schreck, MD, PhD · Johns Hopkins School of Medicine

Eligibility

Min Age
6 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-19
Primary Completion
2023-07-07
Completion
2023-07-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593993 on ClinicalTrials.gov